☆ 4.3 Editorial Material

How do non-coding RNAs impact treatment regimens currently being used in AML?

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

Get Full Text
Add to Collection

Journal

EXPERT REVIEW OF ANTICANCER THERAPY
Volume 22, Issue 4, Pages 331-333

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2022.2049764

Keywords

Acute myeloid leukemia; non-coding RNA; AML risk stratification; AML chemoresistance; targeted therapy

Categories

Oncology

Funding

  1. Austrian Society of Internal Medicine (Joseph-Skoda Award)
  2. Leukamiehilfe Steiermark
  3. Austrian Science Fund [P 31430-458 B26]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.